Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) Equity Average (2016 - 2025)

Mimedx's Equity Average history spans 13 years, with the latest figure at $247.7 million for Q4 2025.

  • For Q4 2025, Equity Average rose 32.44% year-over-year to $247.7 million; the TTM value through Dec 2025 reached $247.7 million, up 32.44%, while the annual FY2025 figure was $224.8 million, 33.9% up from the prior year.
  • Equity Average for Q4 2025 was $247.7 million at Mimedx, up from $227.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $247.7 million in Q4 2025 and bottomed at -$18.8 million in Q4 2022.
  • The 5-year median for Equity Average is -$3.3 million (2021), against an average of $75.9 million.
  • The largest annual shift saw Equity Average plummeted 555.05% in 2022 before it soared 3179.11% in 2024.
  • A 5-year view of Equity Average shows it stood at -$2.9 million in 2021, then tumbled by 555.05% to -$18.8 million in 2022, then skyrocketed by 484.04% to $72.0 million in 2023, then soared by 159.72% to $187.1 million in 2024, then surged by 32.44% to $247.7 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Equity Average are $247.7 million (Q4 2025), $227.8 million (Q3 2025), and $209.7 million (Q2 2025).